Sixfold Bioscience · Jun 2025
Sixfold said it would give the keynote at the 4th Dutch Antisense Therapeutics Symposium.
Delivering RNA therapies.
Public company, workplace, funding, and market signals
Sixfold Bioscience is a London-based preclinical biotech focused on solving RNA delivery, with an AI- and evolution-inspired platform for RNA therapeutics.
Primary product
Mergo® RNA delivery platform
Founded
2017
Headquarters
Translation & Innovation Hub, 84 Wood Ln, London W12 7SL, United Kingdom
Team size
11-50
Industry
Biotechnology Research
Sub-industry
RNA therapeutics / oligonucleotide delivery systems
Offices
2 jobs at Sixfold Bioscience
Business model
Stage
Seed
Total raised
$13.2M
Latest round
Grant · Jul 2024
Leadership
Co-CEO + Founder
Co-CEO + Founder
Chief Business Officer
VP of Research
Investors
Inclusive, diverse, unconventional, collaborative, highly motivated, and focused on solving hard problems.
Compensation
No formal public salary band or benefits page was found. LinkedIn employer data shows compensation reviews around 2.8/5, with example annual salaries for listed roles of about £18.5k (Operations & Finance Assistant), £30.2k (Research Associate), and £34.1k (Office Support).
Differentiators
Technology
Competitors
Estimated revenue
$1M-$10M
Estimated monthly visits
1.7K
Sixfold Bioscience · Jun 2025
Sixfold said it would give the keynote at the 4th Dutch Antisense Therapeutics Symposium.
Sixfold Bioscience · Feb 2025
The company highlighted talks by Dr. Anna Perdrix Rosell and Dr. Reeta Daswani at NextGen Biomed 2025.
Sixfold Bioscience · Feb 2025
Sixfold announced participation at RNA Therapeutics 2025.
Sixfold Bioscience · Jul 2024
The company announced UKRI funding to advance generative ML-enabled RNA delivery research.
Sixfold Bioscience · Nov 2023
The company expanded its lab space in White City to support larger dataset generation and research work.